Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. - Wikidata - wikimedia - TriplyDB

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.

http://www.wikidata.org/entity/Q46690421

about

Pregabalin add-on for drug-resistant partial epilepsy Pregabalin add-on for drug-resistant partial epilepsy The treatment of generalized anxiety disorder with pregabalin, an atypical anxiolytic Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west.Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention.Defining success in clinical trials--profiling pregabalin, the newest AED.Pregabalin: a new neuromodulator with broad therapeutic indications.Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.Effects of pregabalin on visceral pain responses and colonic compliance in rats.New treatment options in the management of fibromyalgia: role of pregabalin.Efficacy and tolerability of pregabalin in partial epilepsy.Pharmacokinetic and pharmacodynamic properties of the new AEDs: A review article Pregabalin in the management of partial epilepsy Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study.Pregabalin for the treatment of postsurgical pain.Pharmacotherapy for children and adolescents with epilepsy.Choice of antiepileptic drugs for the elderly: possible drug interactions and adverse effects.Clinically relevant drug interactions in anxiety disorders.Methodologies used to identify and characterize interactions among antiepileptic drugs.Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy.Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs.Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature.Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder.The Pharmacokinetics of Pregabalin in Breast Milk, Plasma, and Urine of Healthy Postpartum Women.Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies.Pregabalin controlled-release pharmacokinetics in healthy volunteers: analysis of four multiple-dose randomized clinical pharmacology studies.Pregabalin for the management of partial epilepsy.Pregabalin in partial seizures: a pragmatic 21-week, open-label study (PREPS).Pregabalin for the management of neuropathic pain in spinal cord injury.Pregabalin abuse and dependence in Germany: results from a database query.Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study.Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study.Synergistic anticonvulsant effects of pregabalin and amlodipine on acute seizure model of epilepsy in mice.Post-surgical neuropathic pain.Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures.

P2860

Q24197972-EB0E9A7B-0293-4487-9391-FA6F16F12385 Q24242802-F79B9D82-C648-44EE-9509-6F32E337BF5B Q24658278-5A797C9D-5CF2-4F40-93A3-9CF37542497A Q34411257-BE063FD8-7F15-4DFE-AF8B-640B166C1C51 Q34645876-72D1F780-D919-4BFC-9705-1921125FD3A4 Q36249983-96BB1BFE-1056-4965-877D-43E5E4D8C389 Q36313119-5F04DB13-C912-4437-A3E3-268723DB0EDF Q36662893-722493EE-5E69-4663-84C2-EFCA4744E90B Q36938454-1A477E7F-3B51-4F6B-8BC9-D0F58E807BE8 Q37106971-F82CFA8C-A63C-4995-BC82-DAACBAAC1D41 Q37203346-517EB643-9BC2-47C6-8739-1D7B8E457704 Q37311819-0AE68CBE-BF85-4160-A07D-FE1B6C5E8283 Q37318734-1A19B937-D655-430A-B27B-D9C0C3668EE3 Q37641223-5927DC16-2648-4773-B05A-9189B4CB2ADC Q37803241-89D2EC00-0809-479D-98EC-CC5EB6CDA503 Q37826193-49E66AC3-95A9-4A7D-BBB3-0D1198E2D470 Q37969129-CEE9727B-7A6C-4EA6-B169-32FDF12D9B53 Q37981951-D2DA7A8D-0F39-4A64-8B88-3D6C50524A67 Q38018676-E760BF9B-35CA-489E-A142-37DD93F3FC29 Q38064486-3D3C7918-2C1A-46A9-935C-8223B83E31FF Q38115721-54F06470-9DB2-45A0-91AC-5BF63052B906 Q38563874-CE011E7B-32D0-44F5-BD9F-4D47FF33C0AA Q39079619-45AB3788-C1E2-45B2-913C-6F57503DF872 Q39933211-67F9E059-1E86-40AE-A593-1063689EA6A0 Q42674842-EFD5A80C-571A-4A91-8B9D-8609911DBBA4 Q42674848-33E5AC63-9061-471E-97A6-EC56A83BCE6D Q43176295-798685DC-E344-4D74-871A-CEEE8413A872 Q43180448-F2B3986B-BADF-499B-AAAD-770B0CE45E96 Q43922422-6FF5D198-70C0-414D-9E75-FEA0D0C3520F Q44066305-95C79317-92BE-45D8-B31C-1E1807BCF8E7 Q45413391-C52FEA04-D238-434B-B8A5-9CE734D18B28 Q46879499-8D834514-D949-4C60-B8F1-92068B48ABE4 Q48269990-4FF5E2F0-286C-4834-BB47-F115CBA76EFE Q48486589-E9292FF0-816E-44A2-B7D2-C8B3DBD27B68 Q51512695-739A575F-E5D4-4B35-9531-EACE291942DF

P2860

Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.

http://www.wikidata.org/entity/Q46690421

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Pregabalin drug interaction st ...... atients with partial epilepsy.

@en

Pregabalin drug interaction st ...... atients with partial epilepsy.

@nl

type

label

Pregabalin drug interaction st ...... atients with partial epilepsy.

@en

Pregabalin drug interaction st ...... atients with partial epilepsy.

@nl

prefLabel

Pregabalin drug interaction st ...... atients with partial epilepsy.

@en

Pregabalin drug interaction st ...... atients with partial epilepsy.

@nl

P1433

Q46690421-708B807F-305E-4DC4-83BF-F687CFFF420F

P1476

Q46690421-23EADFB2-8549-485E-B77C-8F45E5CA02A4

P2093

Q46690421-0CC2A65E-5240-41F0-96DC-2FD7C8AAF0F1

Q46690421-0E6AAFA8-00E5-463F-AFE2-1D2C713E50D0

Q46690421-1E327103-A792-4911-A8AE-39738751D2A3

Q46690421-467EC150-97F4-45F4-B547-08A93BB9E61D

Q46690421-64698E22-0897-4AD2-A42C-8F4C6A75C2D9

Q46690421-7152A334-2B16-4DA1-8D0A-052DA78E1F4D

Q46690421-727E1C76-46E7-4403-856E-2989375CD6F7

Q46690421-C20D8A88-A54A-41C2-9BB3-CBC4601C4994

Q46690421-DD03055E-6925-4971-9F23-DD6BE2F51B35

Q46690421-EB98B208-0B0A-4501-93C1-D922E0A5330E

P2860

Q46690421-0C4CDEF8-FAFC-4760-A762-2BC4CF92C877

Q46690421-20F44DC8-14FE-4A9F-AC91-1A5279F38B07

Q46690421-2CFC6265-102F-4C21-B373-2F35F1EE0C38

Q46690421-43CCD0AD-209D-401E-B9FF-225F0C5DECB1

Q46690421-47ED9548-841C-45D8-B91A-3CF0B5B0E306

Q46690421-71E854BD-8F48-474D-9F0E-72164897EEF3

Q46690421-895DBC8F-EC5F-4C38-B805-E56015F650D9

Q46690421-A60D7D28-1CA9-468C-A45B-58ABD5802DB0

Q46690421-BF9C44DF-FC45-4711-BDAC-DB306C1B92BA

Q46690421-CB3E95A9-2955-4B0E-84B7-0AF853F7F7F3

P304

Q46690421-5636F775-6D35-4521-95C6-1774E9CBC1A4

P31

Q46690421-22FB6E0A-D66C-414B-B7D4-D382E63E0B5E

P356

Q46690421-D0CD61C9-F343-486E-BCB8-3E231F24663E

P433

Q46690421-9DC2D14B-8B6D-4546-BDB7-87D3E1979E15

P478

Q46690421-1E33CA11-2A50-49E4-AF92-BE1A552E8625

P50

Q46690421-D9B68F93-4675-442C-8C1E-3C35738E0867

P577

Q46690421-09305B2C-0077-48F8-8CBC-D5734FB285DC

P5875

Q46690421-23DA128A-A9B2-4DCE-9A64-FCC5597F53D6

P698

Q46690421-4F2A27B6-1A19-434C-ACE0-E66A5FF96496

P356

J.1528-1167.2005.19204.X

P1433

P1476

Pregabalin drug interaction st ...... atients with partial epilepsy.

@en

P2093

Christine W Alvey

http://www.w3.org/2001/XMLSchema#string

David L Wesche

http://www.w3.org/2001/XMLSchema#string

Edward J Randinitis

http://www.w3.org/2001/XMLSchema#string

Edward L Posvar

http://www.w3.org/2001/XMLSchema#string

Elaine A Wilson

http://www.w3.org/2001/XMLSchema#string

G L Gibson

http://www.w3.org/2001/XMLSchema#string

Howard N Bockbrader

http://www.w3.org/2001/XMLSchema#string

Martin J Brodie

http://www.w3.org/2001/XMLSchema#string

Neil J Hounslow

http://www.w3.org/2001/XMLSchema#string

Nicola J Bron

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

Effectiveness of first antiepileptic drug.

Pharmacokinetics of pregabalin in subjects with various degrees of renal function.

The emerging role of cytochrome P450 3A in psychopharmacology.

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel.

Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices.

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex.

Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices.

Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures.

Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures.

P304

1407-1413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1528-1167.2005.19204.X

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Martin J Brodie

P577

2005-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7615891

http://www.w3.org/2001/XMLSchema#string

P698

16146435

http://www.w3.org/2001/XMLSchema#string